Valneva SE (Nasdaq: VALN) sets Aug. 13 webcast on 2026 first-half results
Rhea-AI Filing Summary
Valneva SE plans to report its first half 2026 financial results on August 13, 2026, and will host a live webcast at 3 p.m. CET / 9 a.m. ET to discuss the results and provide a business update, with an archived replay available on its website.
The company describes itself as a specialty vaccine business focused on prophylactic vaccines for infectious diseases with unmet medical needs. It currently markets three proprietary travel vaccines and is advancing a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a clinically advanced Shigella vaccine candidate.
Positive
- None.
Negative
- None.
Key Figures
First half 2026 results date: August 13, 2026
Webcast time CET: 3 p.m. CET
Webcast time ET: 9 a.m. ET
+2 more
5 metrics
First half 2026 results date
August 13, 2026
Date scheduled for reporting first half 2026 financial results
Webcast time CET
3 p.m. CET
Start time of live webcast discussing first half 2026 results
Webcast time ET
9 a.m. ET
Start time of live webcast in Eastern Time
Proprietary travel vaccines marketed
3
Number of proprietary travel vaccines Valneva currently markets
F-3 registration file number
333-268071
Registration statement into which this report is incorporated by reference
Key Terms
foreign private issuer, Form 6-K, prophylactic vaccines, forward-looking statements, +1 more
5 terms
foreign private issuer regulatory
"FORM 6-K report of foreign private issuer pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Form 6-K regulatory
"Form 6-K report of foreign private issuer under the Exchange Act"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
prophylactic vaccines medical
"commercializes prophylactic vaccines for infectious diseases addressing unmet needs"
forward-looking statements regulatory
"This press release contains certain forward-looking statements relating to the business"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
technology transfer technical
"progress, timing, results and completion of technology transfer and regulatory approvals"
Technology transfer is the process of moving an invention, know‑how, or technical capability from one organization to another so it can be developed, manufactured or sold. For investors it matters because successful transfers turn research or prototypes into marketable products or revenue streams—similar to handing a recipe and kitchen to someone who can scale it up—and they affect a company’s growth prospects, costs, timelines and competitive position.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
When will Valneva (VALN) report its first half 2026 financial results?
Valneva will report its first half 2026 financial results on August 13, 2026. The company plans to discuss these results during a same-day webcast that will also include a broader business update for investors and other stakeholders.
What time is Valneva’s (VALN) first half 2026 results webcast?
The webcast is scheduled to begin at 3 p.m. CET / 9 a.m. ET on August 13, 2026. During this live event, management will review first half 2026 financial results and provide a business update, with access available through Valneva’s website.
How can investors access Valneva (VALN)’s August 13, 2026 webcast and replay?
Investors can access the live webcast via a link on Valneva’s website. After the August 13, 2026 event concludes, the company states that an archived version of the webcast will be made available online for later viewing.
What type of company is Valneva (VALN)?
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. It applies a targeted approach across multiple vaccine modalities to deliver first-, best-, or only-in-class vaccine solutions.
Which vaccines and pipeline candidates does Valneva (VALN) highlight?
Valneva highlights that it markets three proprietary travel vaccines and is advancing a pipeline including a Lyme disease vaccine candidate partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, and additional candidates against other global public health threats.